

# The role of early nutrition on the development of very low birth weight newborns

<b>Submission date</b> 03/04/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 12/04/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 21/05/2026	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Survival rates of babies born prematurely are increasing, but long-term consequences of pre-term birth may persist throughout life. The ideal growth of a premature newborn is considered to be the same as the intrauterine growth of the fetus. However, a premature infant experiences a high level of stress and inadequate nutrition during the hospitalization period despite recommended high nutrient intake. Morbidity during the early neonatal period has a negative impact on growth and neurodevelopment. Optimization of nutrition should improve long-term outcomes. The aim of this study is to look for reliable nutrition assessment markers and evaluate the role of early nutrition on growth, body composition and neurodevelopmental outcomes.

### Who can participate?

Very low birth weight (less than 1500 g) newborns born in the Hospital of Lithuanian University of Health Sciences Kauno klinikos can participate in this study, if both parents sign the informed consent. The infant will participate in the study until 12 months corrected gestational age, i.e. until 12 months starting count from the due date. Newborns with congenital anomalies will not be included.

### What does the study involve?

The study is non interventional. All newborns receive the same care and feeding regimens according to their clinical condition. Mother's own milk is analyzed for protein, carbohydrates, fat and calories weekly, intravenous and oral intake is calculated daily. Standard measures, such as weight, length and head circumference is checked weekly as well as detailed measurements of upper arm, thigh circumference, lower leg length and skinfold on 4 sites. Blood specimens for hormones affecting growth and adipose tissue accumulation (1 ml of blood) is drawn at 1, 2, 4, 6, 8 weeks or until discharge. Neurodevelopment will be assessed using standardized scales at 12 months corrected gestational age.

### What are the possible benefits and risks of participating?

Since there is no intervention, no particular benefit will be from the enrollment. There is a small

risk of bleeding, infection and short-term pain during the blood draw. Pain relief measures are always applied before blood draw. Also there are very small doses of additional radiation during DXA imaging.

Where is the study run from?

The study is running in the Hospital of Lithuanian University of Health Sciences Kauno klinikos.

When is the study starting and how long is it expected to run for?

May 2018 to September 2024

Who is funding the study?

The study is funded by Hospital of Lithuanian University of Health Sciences Kauno klinikos.

Who is the main contact?

The main contact is doctor Rasa Brinkis, [rasa.brinkis@lsmuni.lt](mailto:rasa.brinkis@lsmuni.lt)

## Contact information

### Type(s)

Scientific

### Contact name

Mrs Rasa Brinkis

### ORCID ID

<https://orcid.org/0000-0002-8812-0562>

### Contact details

Eiveniu 2

Kaunas

Lithuania

50009

+37037327201

[rasa.brinkis@lsmuni.lt](mailto:rasa.brinkis@lsmuni.lt)

## Additional identifiers

### Protocol serial number

BE-2-12

## Study information

### Scientific Title

The role of early nutrition on metabolic markers and hormones, growth and neurocognitive development of very low birth weight newborns

### Acronym

RENHGD

### Study objectives

The aim of this study is to determine the relationship between early nutrition (evaluating amounts of parenteral and enteral intakes of protein and calories during hospitalisation period), metabolic markers and hormones (glucose, insulin, IGF-1, IGFBP-3, leptin, ghrelin, adiponectin), growth, body composition, morbidity and neurodevelopmental outcomes among VLBW infants.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 28/02/2018, Kaunas Regional Biomedical Research Ethics Committee (A. Mickevičius str. 9, LT-44307 Kaunas (406 room); kaunorbtek@lsmuni.lt; +370 615 81669), ref: BE-2-12

### **Primary study design**

Observational

### **Study design**

Observational longitudinal cohort study

### **Study type(s)**

Quality of life

### **Health condition(s) or problem(s) studied**

Growth and neurodevelopment of very low birth weight (<1500 g) newborns

### **Interventions**

Cord blood sample for glucose, insulin, IGF-1, IGFBP-3, leptin, ghrelin, adiponectin and DNA extraction is drawn after birth of very low birthweight newborns. Daily nutritional data are evaluated, composition of mother's own milk or donor milk is analyzed weekly, general anthropometric measures (weight, length, head circumference) as well as detailed anthropometric measures (mid-upper-arm circumference, mid-thigh circumference, lower leg length and 4 site skinfold) are performed weekly. 1 ml of blood at 1, 2, 4, 6 and 8 weeks after birth and 12 months corrected gestational age is drawn for glucose, insulin, IGF-1, IGFBP-3, leptin, ghrelin, adiponectin testing. BUN is a part of routine nutritional screening and these data as well as morbidity such as sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity are collected from medical records. At discharge and 12 months corrected gestational age DXA analysis for body composition is performed. At 12 months corrected gestational age neurodevelopment is assessed using Bayley II scale.

### **Intervention Type**

Not Specified

### **Primary outcome(s)**

1. Growth restriction at discharge measured using Fenton growth charts
2. Body composition at discharge measured using DXA analysis.

### **Key secondary outcome(s)**

1. At 12 months corrected gestational age neurodevelopment is assessed using Bayley II scale.

### **Completion date**

30/09/2024

# Eligibility

## Key inclusion criteria

1. Very low birth weight newborns (<1500g), both AGA and SGA, born in Kaunas Perinatal centre.
2. Parental consent acquired.

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Neonate

## Sex

All

## Total final enrolment

120

## Key exclusion criteria

1. Congenital malformations
2. Posthaemorrhagic hydrocephalus
3. Abdominal surgery resulting in part of the bowel resection

## Date of first enrolment

31/05/2018

## Date of final enrolment

19/05/2020

# Locations

## Countries of recruitment

Lithuania

## Study participating centre

Hospital of Lithuanian University of Health Sciences Kauno klinikos

Eiveniu 2

Kaunas

Lithuania

50009

# Sponsor information

## Organisation

Lithuanian University of Health Sciences

## ROR

<https://ror.org/0069bkg23>

## Funder(s)

### Funder type

University/education

### Funder Name

Lithuanian University of Health Sciences

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Rasa Brinkis, e-mail: [rasa.brinkis@lsmuni.lt](mailto:rasa.brinkis@lsmuni.lt), data will be in MS Excel format, available by July/August 2020, the follow-up data will be available November 2021.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		13/05/2024	06/09/2024	Yes	No
<a href="#">Results article</a>		11/03/2022	21/05/2026	Yes	No
<a href="#">Results article</a>		06/09/2022	21/05/2026	Yes	No
<a href="#">Preprint results</a>		16/04/2024	02/05/2024	No	No